Nasopharyngeal carcinoma (NPC) is a highly aggressive malignancy, with most patients presenting at locally advanced stages. While immune checkpoint inhibitors, such as PD-1 blockade, have reshaped treatment strategies, only a minority of patients achieve durable benefit. Accurate biomarkers for predicting treatment response remain an urgent unmet need.